vs
Axogen, Inc.（AXGN）与IRIDEX CORP（IRIX）财务数据对比。点击上方公司名可切换其他公司
Axogen, Inc.的季度营收约是IRIDEX CORP的4.1倍（$59.9M vs $14.7M），Axogen, Inc.同比增速更快（21.3% vs -69.7%），过去两年Axogen, Inc.的营收复合增速更高（20.3% vs 11.9%）
Axogen总部位于美国佛罗里达州阿拉楚阿，是外科解决方案提供商，专注开发周围神经损伤修复相关产品，涵盖人体组织移植物、神经连接器、软组织膜等，旗下AVANCE细胞移植技术可模拟人体神经结构，临床数据显示其产品帮助87%的周围神经损伤患者实现感觉与运动功能恢复，2013年完成1800万美元首次公开募股。
IRIDEX Corporation是一家全球性医疗科技企业，主要研发、生产和销售面向眼科及医疗美容领域的激光类医疗设备，产品供应至北美、欧洲、亚太等地区的医疗机构与诊所，为眼部疾病治疗和医美项目提供微创解决方案。
AXGN vs IRIX — 直观对比
营收规模更大
AXGN
是对方的4.1倍
$14.7M
营收增速更快
AXGN
高出91.0%
-69.7%
两年增速更快
AXGN
近两年复合增速
11.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $59.9M | $14.7M |
| 净利润 | $-13.2M | — |
| 毛利率 | 74.1% | 37.2% |
| 营业利润率 | -16.3% | — |
| 净利率 | -22.0% | — |
| 营收同比 | 21.3% | -69.7% |
| 净利润同比 | -3023.6% | — |
| 每股收益（稀释后） | $-0.28 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AXGNIRIX
| Q4 25 | $59.9M | $14.7M | ||
| Q3 25 | $60.1M | $12.5M | ||
| Q2 25 | $56.7M | $13.6M | ||
| Q1 25 | $48.6M | $11.9M | ||
| Q4 24 | $49.4M | $12.7M | ||
| Q3 24 | $48.6M | $11.6M | ||
| Q2 24 | $47.9M | $12.6M | ||
| Q1 24 | $41.4M | $11.8M |
净利润AXGNIRIX
| Q4 25 | $-13.2M | — | ||
| Q3 25 | $708.0K | $-1.6M | ||
| Q2 25 | $579.0K | $-994.0K | ||
| Q1 25 | $-3.8M | $-1.7M | ||
| Q4 24 | $450.0K | $-834.0K | ||
| Q3 24 | $-1.9M | $-1.9M | ||
| Q2 24 | $-1.9M | $-2.7M | ||
| Q1 24 | $-6.6M | $-3.5M |
毛利率AXGNIRIX
| Q4 25 | 74.1% | 37.2% | ||
| Q3 25 | 76.6% | 32.1% | ||
| Q2 25 | 74.2% | 34.5% | ||
| Q1 25 | 71.9% | 42.5% | ||
| Q4 24 | 76.1% | 44.0% | ||
| Q3 24 | 74.9% | 37.3% | ||
| Q2 24 | 73.8% | 40.7% | ||
| Q1 24 | 78.8% | 37.9% |
营业利润率AXGNIRIX
| Q4 25 | -16.3% | — | ||
| Q3 25 | 3.2% | -11.3% | ||
| Q2 25 | 3.0% | -6.9% | ||
| Q1 25 | -3.4% | -1.7% | ||
| Q4 24 | 4.1% | -3.9% | ||
| Q3 24 | -0.6% | -16.1% | ||
| Q2 24 | -0.9% | -20.9% | ||
| Q1 24 | -11.0% | -28.0% |
净利率AXGNIRIX
| Q4 25 | -22.0% | — | ||
| Q3 25 | 1.2% | -12.6% | ||
| Q2 25 | 1.0% | -7.3% | ||
| Q1 25 | -7.9% | -14.2% | ||
| Q4 24 | 0.9% | -6.6% | ||
| Q3 24 | -3.8% | -16.7% | ||
| Q2 24 | -4.0% | -21.2% | ||
| Q1 24 | -16.0% | -29.5% |
每股收益（稀释后）AXGNIRIX
| Q4 25 | $-0.28 | — | ||
| Q3 25 | $0.01 | $-0.09 | ||
| Q2 25 | $0.01 | $-0.06 | ||
| Q1 25 | $-0.08 | $-0.10 | ||
| Q4 24 | $-0.00 | $-0.05 | ||
| Q3 24 | $-0.04 | $-0.12 | ||
| Q2 24 | $-0.04 | $-0.16 | ||
| Q1 24 | $-0.15 | $-0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $41.5M | $6.0M |
| 总债务越低越好 | $48.4M | — |
| 股东权益账面价值 | $128.8M | — |
| 总资产 | $221.7M | $29.2M |
| 负债/权益比越低杠杆越低 | 0.38× | — |
8季度趋势，按日历期对齐
现金及短期投资AXGNIRIX
| Q4 25 | $41.5M | $6.0M | ||
| Q3 25 | $35.8M | $5.6M | ||
| Q2 25 | $29.9M | $6.8M | ||
| Q1 25 | $22.1M | $7.2M | ||
| Q4 24 | $33.5M | $2.4M | ||
| Q3 24 | $24.5M | $3.9M | ||
| Q2 24 | $21.1M | $4.1M | ||
| Q1 24 | $17.6M | $5.4M |
总债务AXGNIRIX
| Q4 25 | $48.4M | — | ||
| Q3 25 | $48.2M | — | ||
| Q2 25 | $47.9M | — | ||
| Q1 25 | $47.7M | — | ||
| Q4 24 | $47.5M | $1.0M | ||
| Q3 24 | $47.3M | $1.4M | ||
| Q2 24 | $47.0M | — | ||
| Q1 24 | $46.8M | — |
股东权益AXGNIRIX
| Q4 25 | $128.8M | — | ||
| Q3 25 | $120.8M | $4.7M | ||
| Q2 25 | $112.3M | $6.1M | ||
| Q1 25 | $105.4M | $852.0K | ||
| Q4 24 | $103.9M | $2.1M | ||
| Q3 24 | $99.4M | $2.6M | ||
| Q2 24 | $95.7M | $4.2M | ||
| Q1 24 | $93.2M | $6.5M |
总资产AXGNIRIX
| Q4 25 | $221.7M | $29.2M | ||
| Q3 25 | $216.4M | $28.4M | ||
| Q2 25 | $205.5M | $31.6M | ||
| Q1 25 | $196.2M | $34.2M | ||
| Q4 24 | $203.7M | $29.1M | ||
| Q3 24 | $192.0M | $30.2M | ||
| Q2 24 | $188.9M | $31.2M | ||
| Q1 24 | $186.5M | $34.1M |
负债/权益比AXGNIRIX
| Q4 25 | 0.38× | — | ||
| Q3 25 | 0.40× | — | ||
| Q2 25 | 0.43× | — | ||
| Q1 25 | 0.45× | — | ||
| Q4 24 | 0.46× | 0.48× | ||
| Q3 24 | 0.48× | 0.53× | ||
| Q2 24 | 0.49× | — | ||
| Q1 24 | 0.50× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $3.0M | — |
| 自由现金流经营现金流 - 资本支出 | $1.8M | — |
| 自由现金流率自由现金流/营收 | 3.0% | — |
| 资本支出强度资本支出/营收 | 2.1% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-2.9M | — |
8季度趋势，按日历期对齐
经营现金流AXGNIRIX
| Q4 25 | $3.0M | — | ||
| Q3 25 | $3.2M | $-1.2M | ||
| Q2 25 | $7.7M | $-397.0K | ||
| Q1 25 | $-13.2M | $-1.1M | ||
| Q4 24 | $8.7M | $-1.2M | ||
| Q3 24 | $3.9M | $-3.1M | ||
| Q2 24 | $4.2M | $-1.3M | ||
| Q1 24 | $-12.3M | $-1.6M |
自由现金流AXGNIRIX
| Q4 25 | $1.8M | — | ||
| Q3 25 | $1.7M | $-1.2M | ||
| Q2 25 | $7.0M | $-410.0K | ||
| Q1 25 | $-13.4M | $-1.2M | ||
| Q4 24 | $8.1M | $-1.2M | ||
| Q3 24 | $3.3M | $-3.1M | ||
| Q2 24 | $3.3M | — | ||
| Q1 24 | $-13.2M | $-1.7M |
自由现金流率AXGNIRIX
| Q4 25 | 3.0% | — | ||
| Q3 25 | 2.8% | -9.4% | ||
| Q2 25 | 12.4% | -3.0% | ||
| Q1 25 | -27.7% | -9.8% | ||
| Q4 24 | 16.3% | -9.8% | ||
| Q3 24 | 6.8% | -26.5% | ||
| Q2 24 | 6.8% | — | ||
| Q1 24 | -31.9% | -14.0% |
资本支出强度AXGNIRIX
| Q4 25 | 2.1% | — | ||
| Q3 25 | 2.5% | 0.1% | ||
| Q2 25 | 1.3% | 0.1% | ||
| Q1 25 | 0.5% | 0.1% | ||
| Q4 24 | 1.4% | 0.1% | ||
| Q3 24 | 1.2% | 0.0% | ||
| Q2 24 | 1.9% | 0.0% | ||
| Q1 24 | 2.2% | 0.0% |
现金转化率AXGNIRIX
| Q4 25 | — | — | ||
| Q3 25 | 4.55× | — | ||
| Q2 25 | 13.35× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 19.41× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
